<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:e sem="disease" ids="C0010823" disease_type="Disease or Syndrome" abbrv="">Cytomegalovirus infection</z:e> (CMV-I) and CMV related diseases (CMV-D) occurred after allogeneic hematopoietic stem cell transplantation (Allo-HSCT) seem to be with high morbidity and mortality </plain></SENT>
<SENT sid="1" pm="."><plain>This study is a retrospective analysis of the incidence of <z:e sem="disease" ids="C0010823" disease_type="Disease or Syndrome" abbrv="">CMV infection</z:e> and diseases in Allo-HSCT patients known to be CMV seropositive before transplantation </plain></SENT>
<SENT sid="2" pm="."><plain>To review the efficacy of CMV pp65 antigen-guided <z:chebi fb="0" ids="465284">ganciclovir</z:chebi> prophylaxis in preventing <z:e sem="disease" ids="C0010823" disease_type="Disease or Syndrome" abbrv="">CMV infection</z:e> and to search the optimal determination methods, 45 consecutive Allo-HSCT patients have been observed </plain></SENT>
<SENT sid="3" pm="."><plain>Using the CMV pp65 antigenemia assay and serological analysis monitored blood samples from 23 patients with <z:hpo ids='HP_0011010'>chronic</z:hpo> myeloid <z:hpo ids='HP_0001909'>leukemia</z:hpo> (<z:mp ids='MP_0005481'>CML</z:mp>), 7 <z:hpo ids='HP_0004808'>acute myeloblastic leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>), 6 <z:hpo ids='HP_0006721'>acute lymphoblastic leukemia</z:hpo> (ALL); other: 4 <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>), 3 non-Hodgkin's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (NHL) and 2 <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo> </plain></SENT>
<SENT sid="4" pm="."><plain>Forty-three patients received HLA-identical siblings transplantation and 2 from their HLA-haploidentical donors </plain></SENT>
<SENT sid="5" pm="."><plain>Forty-five cases included Allo-PBPCT (38 cases), Allo-BMT (2 cases) and Allo-PBPCT + BMT 5 cases </plain></SENT>
<SENT sid="6" pm="."><plain>Before transplantation, <z:hpo ids='HP_0000001'>all</z:hpo> donors/recipients have taken CMV serological detection </plain></SENT>
<SENT sid="7" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> donor/recipients were CMV IgG positive and one donor and one recipient with CMV IgM positive, respectively </plain></SENT>
<SENT sid="8" pm="."><plain>After transplantation, <z:hpo ids='HP_0000001'>all</z:hpo> patients developed CMV antigenemia during monitoring period </plain></SENT>
<SENT sid="9" pm="."><plain>Twenty-five patients developed CMV related interstitial <z:hpo ids='HP_0002090'>pneumonia</z:hpo> (CMV-IP) </plain></SENT>
<SENT sid="10" pm="."><plain>Patients have been followed from 6 to 28 months (median of 18 months) after transplantation </plain></SENT>
<SENT sid="11" pm="."><plain>The patients who received preemptive therapy had a significantly better outcome than patients who did not received preemptive therapy </plain></SENT>
<SENT sid="12" pm="."><plain>CMV related mortality was 1/29 cases in preemptive group vs. 12/16 cases in non-preemptive group </plain></SENT>
<SENT sid="13" pm="."><plain>The results suggest that prompt and early institution of effective therapy with <z:chebi fb="0" ids="465284">ganciclovir</z:chebi> upon detection of CMV pp65 antigenemia, provides optimal protection against progress of CMV disease for patients undergoing Allo-HSCT </plain></SENT>
</text></document>